Health

Biotech News

Updated 2026-06-29 14:10 UTC 1 source Neutral

Moderna remains optimistic about its mRNA technology and the acquisition of Kartos by Ipsen. Talawar is betting on a bispecific approach to shake up the eczema market.

Coverage timeline — 1 article

STAT News

STAT+: Talawar bets bispecific approach can shake up eczema market

Moderna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout

2026-06-29 13:52 UTC